Emerging monoclonal antibody therapies for malignant gliomas

Expert Opinion on Investigational Drugs

Volumn 16, Issue 4, 2007, Pages 477-494

  Gerber, David E ^a   Laterra, John ^a,b  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antibody dependent cellular cytotoxicity; Blood brain barrier; Brain tumor; Glioma; Monoclonal antibody; Radioisotope; Receptor tyrosine kinase; Targeted therapy

Indexed keywords

ALEMTUZUMAB; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CARMUSTINE; CELL SURFACE PROTEIN; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMATINIB; IMMUNOTOXIN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 3F8; MONOCLONAL ANTIBODY 81C6 I 131; MONOCLONAL ANTIBODY BC 2 I 131; MONOCLONAL ANTIBODY BC 4 I 131; MONOCLONAL ANTIBODY KM966; MONOCLONAL ANTIBODY TGN 1412; OKT 3; PANITUMUMAB; PROTEIN TYROSINE KINASE; RITUXIMAB; SCATTER FACTOR; TEMOZOLOMIDE; TENASCIN; TOSITUMOMAB; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ANTIBODY DIRECTED ENZYME PRODRUG THERAPY; BLOOD BRAIN BARRIER; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; DRUG CLEARANCE; DRUG DESIGN; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG TARGETING; GLIOBLASTOMA; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; LUNG CANCER; MULTIPLE CYCLE TREATMENT; MULTIPLE ORGAN FAILURE; NEUROTOXICITY; NONHODGKIN LYMPHOMA; NONHUMAN; OLIGODENDROGLIOMA; PROTEIN TARGETING; RADIOIMMUNOTHERAPY; REVIEW; RHEUMATOID ARTHRITIS; SURVIVAL RATE; SURVIVAL TIME; TREATMENT DURATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, NEOPLASM; DRUG DELIVERY SYSTEMS; GLIOMA; HUMANS;

EID: 34147150749     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.16.4.477     Document Type: Review

References (116)

1. NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 1: growth factor and ras signaling pathways. Expert Rev. Anticancer Ther. (2003) 3(5):595-614.
2. NEWTON HB: Molecular neuro-oncology and development of targeted therapeutic strategies for brain tumors. Part 2: PI3K/Akt/PTEN, mTOR, SHH/PTCH and angiogenesis. Expert Rev. Anticancer Ther. (2004) 4(1):105-128.
3. KONDO Y, HOLLINGSWORTH EF, KONDO S: Molecular targeting for malignant gliomas (review). Int. J. Oncol. (2004) 24(5):1101-1109.
4. BOSKOVITZ A, WIKSTRAND CJ, KUAN CT, ZALUTSKY MR, REARDON DA, BIGNER DD: Monoclonal antibodies for brain tumour treatment. Expert Opin. Biol. Ther. (2004) 4(9):1453-1471.
5. BUTOWSKI N, CHANG SM: Small molecule and monoclonal antibody therapies in neurooncology. Cancer Control (2005) 12(2):116-124.
6. MISCHEL PS, CLOUGHESY TF: Targeted molecular therapy of GBM. Brain Pathol. (2003) 13(1):52-61.
7. REARDON DA, WEN PY: Therapeutic advances in the treatment of glioblastoma: rationale and potential role of targeted agents. Oncologist (2006) 11(2):152-164.
8. PRASAD G, WANG H, HILL DL, ZHANG R: Recent advances in experimental molecular therapeutics for malignant gliomas. Curr. Med. Chem. Anticancer Agents (2004) 4(4):347-361.
9. TANNER JE: Designing antibodies for oncology. Cancer Metastasis Rev. (2005) 24(4):585-598.
10. HOPKIN M: Can super-antibody drugs be tamed? Nature (2006) 240:855-856.
11. CARTER P: Improving the efficacy of antibody-based cancer therapies. Nat. Rev. Cancer (2001) 1(2):118-129.
12. 131I-labeled antitenascin monoclonal antibody 81C6 administered into surgically created resection cavities of patients with newly diagnosed malignant gliomas. J. Clin. Oncol. (2002) 20(5):1389-1397.
13. WERSALL P, OHLSSON I, BIBERFELD P et al.: Intratumoral infusion of the monoclonal antibody, mAb 425, against the epidermal-growth-factor receptor in patients with advanced malignant glioma. Cancer Immunol. Immunother. (1997) 44(3):157-164.
14. 131I: comparison of the results obtained in recurrent and newly diagnosed tumors. Cancer Res. (1995) 55(Suppl. 23):5952s-5956s.
15. DAN MD, SCHLACHTA CM, GUY J et al.: Human antiglioma monoclonal antibodies from patients with astrocytic tumors. J. Neurosurg. (1992) 76(4):660-669.
16. WU AM, SENTER PD: Arming antibodies: prospects and challenges for immunoconjugates. Nat. Biotechnol. (2005) 23(9):1137-1146.
17. GOETZ CM, RACHINGER W, DECKER M et al.: Distribution of labelled anti-tenascin antibodies and fragments after injection into intact or partly resected C6-gliomas in rats. Cancer Immunol. Immunother. (2005) 54(4):337-344.
18. COLCHER D, PAVLINKOVA G, BERESFORD G, BOOTH BJ, CHOUDHURY A, BATRA SK: Pharmacokinetics and biodistribution of genetically-engineered antibodies. QJ Nucl. Med. (1998) 42(4):225-241.
19. MARTENS T, SCHMIDT NO, ECKERICH C et al.: A novel one-armed anti-c-met antibody inhibits glioblastoma growth in vivo. Clin. Cancer Res. (2006) 12(20 Part 1):6144-6152.
20. MAMOT C, DRUMMOND DC, NOBLE CO et al.: Epidermal growth factor receptor-targeted immunoliposomes significantly enhance the efficacy of multiple anticancer drugs in vivo. Cancer Res. (2005) 65(24):11631-11638.
21. ZALUTSKY MR, MOSELEY RP, BENJAMIN JC et al.: Monoclonal antibody and F(ab′)2 fragment delivery to tumor in patients with glioma: comparison of intracarotid and intravenous administration. Cancer Res. (1990) 50(13):4105-4110.
22. REIST CJ, ARCHER GE, WIKSTRAND CJ, BIGNER DD, ZALUTSKY MR: Improved targeting of an anti-epidermal growth factor receptor variant III monoclonal antibody in tumor xenografts after labeling using N-succinimidyl 5-iodo-3-pyridinecarboxylate. Cancer Res. (1997) 57(8):1510-1515.
23. LEE SW, FRAASS BA, MARSH LH et al.: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int. J. Radiat. Oncol. Biol. Phys. (1999) 43(1):79-88.
24. 90Y MoAbs into glioma tumor resection cavities leads to limited diffusion of the radioimmunoconjugates into normal brain parenchyma: a model to estimate absorbed radiation dose. Int. J. Radiat. Oncol. Biol. Phys. (1998) 40(4):835-844.
25. LAMBERT JM: Drug-conjugated monoclonal antibodies for the treatment of cancer. Curr. Opin. Pharmacol. (2005) 5(5):543-549.
26. SCHAEDEL O, REITER Y: Antibodies and their fragments as anti-cancer agents. Curr. Pharm. Des. (2006) 12(3):363-378.
27. RUSTAMZADEH E, LOW WC, VALLERA DA, HALL WA: Immunotoxin therapy for CNS tumor. J. Neurooncol. (2003) 64(1-2):101-116.
28. TAKAHASHI H, ADACHI K, YAMAGUCHI F, TERAMOTO A: Experimental treatment of malignant gliomas with human monoclonal antibody-drug conjugates. Anticancer Res. (1999) 19(5B):4151-4155.
29. WU G, BARTH RF, YANG W, KAWABATA S, ZHANG L, GREEN-CHURCH K: Targeted delivery of methotrexate to epidermal growth factor receptor-positive brain tumors by means of cetuximab (IMC-C225) dendrimer bioconjugates. Mol. Cancer Ther. (2006) 5(1):52-59.
30. LASKE DW, ILERCIL O, AKBASAK A, YOULE RJ, OLDFIELD EH: Efficacy of direct intratumoral therapy with targeted protein toxins for solid human gliomas in nude mice. J. Neurosurg. (1994) 80(3):520-526.
31. FOEHR ED, LORENTE G, KUO J, RAM R, NIKOLICH K, URFER R: Targeting of the receptor protein tyrosine phosphatase β with a monoclonal antibody delays tumor growth in a glioblastoma model. Cancer Res. (2006) 66(4):2271-2278.
32. MAMOT C, DRUMMOND DC, GREISER U et al.: Epidermal growth factor receptor (EGFR)-targeted immunoliposomes mediate specific and efficient drug delivery to EGFR- and EGFRvIII-overexpressing tumor cells. Cancer Res. (2003) 63(12):3154-3161.
33. GRANA C, CHINOL M, ROBERTSON C et al.: Pretargeted adjuvant radioimmunotherapy with yttrium-90-biotin in malignant glioma patients: a pilot study. Br. J. Cancer (2002) 86(2):207-212.
34. PAGANELLI G, GRANA C, CHINOL M et al.: Antibody-guided three-step therapy for high grade glioma with yttrium-90 biotin. Eur. J. Nucl. Med. (1999) 26(4):348-357.
35. DI GAETANO N, CITTERA E, NOTA R et al.: Complement activation determines the therapeutic activity of rituximab in vivo. J. Immunol. (2003) 171(3):1581-1587.
36. CLYNES RA, TOWERS TL, PRESTA LG, RAVETCH JV: Inhibitory fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med. (2000) 6(4):443-446.
37. SAMPSON JH, CROTTY LE, LEE S et al.: Unarmed, tumor-specific monoclonal antibody effectively treats brain tumors. Proc. Natl. Acad Sci. USA (2000) 97(13):7503-7508.
38. TAKAHASHI H, BELSER PH, ATKINSON BF et al.: Monoclonal antibody-dependent, cell-mediated cytotoxicity against human malignant gliomas. Neurosurgery (1990) 27(1):97-102.
39. CLAYTON AJ, DANSON S, JOLLY S et al.: Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br. J. Cancer (2004) 91(4):639-643.
40. BENDELL JC, DOMCHEK SM, BURSTEIN HJ et al.: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer (2003) 97(12):2972-2977.
41. 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma. Expert Opin. Biol. Ther. (2006) 6(5):539-545.
42. PATEL SJ, SHAPIRO WR, LASKE DW et al.: Safety and feasibility of convection-enhanced delivery of cotara for the treatment of malignant glioma: initial experience in 51 patients. Neurosurgery (2005) 56(6):1243-1252 (Discussion 1252-1253).
43. YANG W, BARTH RF, WU G et al.: Development of a syngeneic rat brain tumor model expressing EGFRvIII and its use for molecular targeting studies with monoclonal antibody L8A4. Clin. Cancer Res. (2005) 11(1):341-350.
44. LEE YS, BULLARD DE, WIKSTRAND CJ, ZALUTSKY MR, MUHLBAIER LH, BIGNER DD: Comparison of monoclonal antibody delivery to intracranial glioma xenografts by intravenous and intracarotid administration. Cancer Res. (1987) 47(7):1941-1946.
45. KIRKPATRICK J, DESJARDINS A, VREDENBURGH JJ et al.: Combination of bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF) and temozolomide: study of cases. J. Clin. Oncol. (2006) 24(Suppl. 18S):11522 (Abstract).
46. VREDENBURGH JJ, DESJARDINS A, HERNDON JE et al.: Bevacizumab, a monoclonal antibody to vascular endothelial growth factor (VEGF), and irinotecan for treatment of malignant gliomas. J. Clin. Oncol. (2006) 24(Suppl. 18S):1506 (Abstract).
47. KIM KJ, WANG L, SU YC et al.: Systemic anti-hepatocyte growth factor monoclonal antibody therapy induces the regression of intracranial glioma xenografts. Clin. Cancer Res. (2006) 12(4):1292-1298.
48. BRADY LW, MIYAMOTO C, WOO DV et al.: Malignant astrocytomas treated with iodine-125 labeled monoclonal antibody 425 against epidermal growth factor receptor: a Phase II trial. Int. J. Radiat. Oncol. Biol. Phys. (1992) 22(1):225-230.
49. BENDER H, EMRICH JG, ESHELMAN J et al.: Enhancement of monoclonal antibody efficacy: the effect of external beam radiation. Hybridoma (1995) 14(2):129-134.
50. DEMATTOS RB, BALES KR, CUMMINS DJ, DODART JC, PAUL SM, HOLTZMAN DM: Peripheral anti-A β antibody alters CNS and plasma A β clearance and decreases brain A β burden in a mouse model of Alzheimer's disease. Proc. Natl. Acad Sci. USA (2001) 98(15):8850-8855.
51. ST CROIX B, RAGO C, VELCULESCU V et al.: Genes expressed in human tumor endothelium. Science (2000) 289(5482):1197-202.
52. MADDEN SL, COOK BP, NACHT M et al.: Vascular gene expression in nonneoplastic and malignant brain. Am. J. Pathol. (2004) 165(2):601-608.
53. BOURDON MA, WIKSTRAND CJ, FURTHMAYR H, MATTHEWS TJ, BIGNER DD: Human glioma-mesenchymal extracellular matrix antigen defined by monoclonal antibody. Cancer Res. (1983) 43(6):2796-2805.
54. LEINS A, RIVA P, LINDSTEDT R, DAVIDOFF MS, MEHRAEIN P, WEIS S: Expression of tenascin-C in various human brain tumors and its relevance for survival in patients with astrocytoma. Cancer (2003) 98(11):2430-2439.
55. HEROLD-MENDE C, MUELLER MM, BONSANTO MM, SCHMITT HP, KUNZE S, STEINER HH: Clinical impact and functional aspects of tenascin-C expression during glioma progression. Int. J. Cancer (2002) 98(3):362-369.
56. HIGUCHI M, OHNISHI T, ARITA N, HIRAGA S, HAYAKAWA T: Expression of tenascin in human gliomas: its relation to histological malignancy, tumor dedifferentiation and angiogenesis. Acta Neuropathol. (Ber.) (1993) 85(5):481-487.
57. 131I-labeled anti-tenascin monoclonal antibody 81C6. Cancer Res. (1988) 48(10):2904-2910.
58. 131I-labeled and-tenascin monoclonal antibody 81C6 in patients with gliomas and other intracranial malignancies. Cancer Res. (1989) 49(10):2807-2813.
59. BIGNER DD, BROWN MT, FRIEDMAN AH et al.: Iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with recurrent malignant gliomas: Phase I trial results. J. Clin. Oncol. (1998) 16(6):2202-2212.
60. REARDON DA, AKABANI G, COLEMAN RE et al.: Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: Phase II study results. J. Clin. Oncol. (2006) 24(1):115-122.
61. 131I and administered into the surgically created resection cavity of patients with malignant glioma: Phase I trial results. J. Nucl. Med. (2006) 47(6):912-918.
62. 131I radioconjugated antibodies for the locoregional radioimmunotherapy of high-grade malignant glioma-Phase I and II study. Acta Oncol. (1999) 38(3):351-359.
63. HEDBERG KM, MAHESPARAN R, READ TA et al.: The glioma associated gangliosides 3′-isoLM1, GD3 and GM2 show selective area expression in human glioblastoma xenografts in nude rat brains. Neuropathol. Appl. Neurobiol. (2001) 27(6):451-464.
64. WIKSTRAND CJ, FREDMAN P, SVENNERHOLM L, BIGNER DD: Detection of glioma-associated gangliosides GM2, GD2, GD3, 3′-isoLM1 3′,6′-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. Prog. Brain Res. (1994) 101:213-223.
65. ARBIT E, CHEUNG NK, YEH SD et al.: Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors. Eur. J. Nucl. Med. (1995) 22(5):419-426.
66. DOHI T, NAKAMURA K, HANAI N, TAOMOTO K, OSHIMA M: Reactivity of a mouse/human chimeric anti-GM2 antibody KM966 with brain tumors. Anticancer Res. (1994) 14(6B):2577-2581.
67. TSUZUKI T, IZUMOTO S, OHNISHI T, HIRAGA S, ARITA N, HAYAKAWA T: Neural cell adhesion molecule L1 in gliomas: correlation with TGF-β and p53. J. Clin. Pathol. (1998) 51(1):13-17.
68. 131I monoclonal antibody: feasibility, pharmacokinetics and dosimetry. Br. J. Cancer (1993) 67(1):144-151.
69. HJORTLAND GO, GARMAN-VIK SS, JUELL S et al.: Immunotoxin treatment targeted to the high-molecular-weight melanoma-associated antigen prolonging the survival of immunodeficient rats with invasive intracranial human glioblastoma multiforme. J. Neurosurg. (2004) 100(2):320-327.
70. HALATSCH ME, SCHMIDT U, BEHNKE-MURSCH J, UNTERBERG A, WIRTZ CR: Epidermal growth factor receptor inhibition for the treatment of glioblastoma multiforme and other malignant brain tumours. Cancer Treat. Rev. (2006) 32(2):74-89.
71. OLIVEIRA S, VAN BERGEN EN HENEGOUWEN PM, STORM G, SCHIFFELERS RM: Molecular biology of epidermal growth factor receptor inhibition for cancer therapy. Expert Opin. Biol. Ther. (2006) 6(6):605-617.
72. BENJAMIN R, CAPPARELLA J, BROWN A: Classification of glioblastoma multiforme in adults by molecular genetics. Cancer J. (2003) 9(2):82-90.
73. SHINOJIMA N, TADA K, SHIRAISHI S et al.: Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. Cancer Res. (2003) 63(20):6962-6970.
74. MELLINGHOFF IK, WANG MY, VIVANCO I et al.: Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. (2005) 353(19):2012-2024.
75. ELLER JL, LONGO SL, HICKLIN DJ, CANUTE GW: Activity of anti-epidermal growth factor receptor monoclonal antibody C225 against glioblastoma multiforme. Neurosurgery (2002) 51(4):1005-1013 (Discussion 1013-1014).
76. FAILLOT T, MAGDELENAT H, MADY E et al. A Phase I study of an anti-epidermal growth factor receptor monoclonal antibody for the treatment of malignant gliomas. Neurosurgery (1996) 39(3):478-483.
77. EMRICH JG, BRADY LW, QUANG TS et al.: Radioiodinated (I-125) monoclonal antibody 425 in the treatment of high grade glioma patients: ten-year synopsis of a novel treatment. Am. J. Clin. Oncol. (2002) 25(6):541-546.
78. CASACO A, LOPEZ G, FERNANDEZ R et al.: Loco-regional radioimmunotherapy of high grade malignant gliomas using the humanized monoclonal antibody, h-R3, labeled with 188-re. Proc. Am. Soc. Clin. Oncol. (2004) 22(14S):2530.
79. RAMOS TC, FIGUEREDO J, CATALA M et al.: Treatment of high-grade glioma patients with the humanized anti-epidermal growth factor receptor (EGFR) antibody h-R3: report from a Phase I/II trial. Cancer Biol. Ther. (2006) 5(4):375-379.
80. BODE U, BUCHEN S, JANSSEN T et al.: Results of a Phase II trial of h-R3 monoclonal antibody (nimotuzumab) in the treatment of resistant or relapsed high-grade gliomas in children and adolescents. J. Clin. Oncol. (2006) 24(Suppl. 18S):1522 (Abstract).
81. PEDERSEN MW, MELTORN M, DAMSTRUP L, POULSEN HS: The type III epidermal growth factor receptor mutation. biological significance and potential target for and-cancer therapy. Ann. Oncol. (2001) 12(6):745-760.
82. KONDO S, MIYATAKE S, IWASAKI K et al.: Human glioma-specific antigens detected by monoclonal antibodies. Neurosurgery (1992) 30(4):506-511.
83. KUAN CT, WIKSTRAND CJ, BIGNER DD: EGFRvIII as a promising target for antibody-based brain tumor therapy. Brain Tumor Pathol. (2000) 17(2):71-78.
84. NISHIKAWA R, JI XD, HARMON RC et al.: A mutant epidermal growth factor receptor common in human glioma confers enhanced tumorigenicity. Proc. Natl. Acad. Sci. USA (1994) 91(16):7727-7731.
85. PERERA RM, NARITA Y, FURNARI FB et al.: Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin. Cancer Res. (2005) 11(17):6390-6399.
86. LUWOR RB, JOHNS TG, MURONE C et al.: Monoclonal antibody 806 inhibits the growth of tumor xenografts expressing either the de2-7 or amplified epidermal growth factor receptor (EGFR) but not wild-type EGFR. Cancer Res. (2001) 61(14):5355-5361.
87. SAMPSON JH, AKABANI G, ARCHER GE et al.: Progress report of a Phase I study of the intracerebral microinfusion of a recombinant chimeric protein composed of transforming growth factor (TGF)-α and a mutated form of the pseudomonas exotoxin termed PE-38 (TP-38) for the treatment of malignant brain tumors. J. Neurooncol. (2003) 65(1):27-35.
88. TAKASU S, TAKAHASHI T, OKAMOTO S et al.: Radioimmunoscintigraphy of intracranial glioma xenograft with a technetium-99m-labeled mouse monoclonal antibody specifically recognizing type III mutant epidermal growth factor receptor. J. Neurooncol. (2003) 63(3):247-256.
89. CARDONES AR, BANEZ LL: VEGF inhibitors in cancer therapy. Curr. Pharm. Des. (2006) 12(3):387-394.
90. PUROW B, FINE HA: Progress report on the potential of angiogenesis inhibitors for neuro-oncology. Cancer Invest. (2004) 22(4):577-587.
91. HURWITZ H, FEHRENBACHER L, CARTWRIGHT T et al.: Wound healing/ bleeding in metastatic colorectal cancer patients who undergo surgery during treatment with bevacizumab. J. Clin. Oncol. 2004 ASCO Annual Meeting Proceedings (Post-Meeting Edition) (2004) 22 (Suppl. 14S):3702.
92. JOHNSON DH, FEHRENBACHER L, NOVOTNY WF et al.: Randomized Phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J. Clin. Oncol. (2004) 22(11):2184-2191.
93. POPE WB, LAI A, NGHIEMPHU P, MISCHEL P, CLOUGHESY TF: MRI in patients with high-grade gliomas treated with bevacizumab and chemotherapy. Neurology (2006) 66(8):1258-1260.
94. HICKLIN DJ, ELLIS LM: Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J. Clin. Oncol. (2005) 23(5):1011-1027.
95. JAIN RK: Molecular regulation of vessel maturation. Nat. Med. (2003) 9(6):685-693.
96. LAMSZUS K, KUNKEL P, WESTPHAL M: Invasion as limitation to anti-angiogenic glioma therapy. Acta Neurochir. Suppl. (2003) 88:169-177.
97. KUNKEL P, ULBRICHT U, BOHLEN P et al. Inhibition of glioma angiogenesis and growth in vivo by systemic treatment with a monoclonal antibody against vascular endothelial growth factor receptor-2. Cancer Res. (2001) 61(18):6624-6628.
98. KOZIN SV, BOUCHER Y, HICKLIN DJ, BOHLEN P, JAIN RK, SUIT HD: Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografs. Cancer Res. (2001) 61(1):39-44.
99. ABOUNADER R, RANGANATHAN S, LAL B et al.: Reversion of human glioblastoma malignancy by U1 small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. (1999) 91(18):1548-1556.
100. BOWERS DC, FAN S, WALTER KA et al.: Scatter factor/hepatocyte growth factor protects against cytotoxic death in human glioblastoma via phosphatidylinositol 3-kinase- and AKT-dependent pathways. Cancer Res. (2000) 60(15):4277-4283.
101. BIRCHMEIER C, BIRCHMEIER W, GHERARDI E, VANDE WOUDE GF: Met, metastasis, motility and more. Nat. Rev. Mol. Cell Biol. (2003) 4(12):915-925.
102. LAMSZUS K, SCHMIDT NO, JIN L et al.: Scatter factor promotes motility of human glioma and neuromicrovascular endothelial cells. Int. J. Cancer (1998) 75(1):19-28.
103. ABOUNADER R, LATERRA J: Scatter factor/hepatocyte growth factor is brain tumor growth and angiogenesis. Neuro-oncol. (2005) 7(4):436-451.
104. CAO B, SU Y, OSKARSSON M et al.: Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. USA (2001) 98(13):7443-7448.
105. BURGESS T, COXON A, MEYER S et al.: Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-met-dependent human tumors. Cancer Res. (2006) 66(3):1721-1729.
106. TAKAHASHI JA, FUKUMOTO M, KOZAI Y et al.: Inhibition of cell growth and tumorigenesis of human glioblastoma cells by a neutralizing antibody against human basic fibroblast growth factor. FEBS Lett. (1991) 288(1-2):65-71.
107. BREYER R, HUSSEIN S, RADU DL et al.: Disruption of intracerebral progression of C6 rat glioblastoma by in vivo treatment with anti-CD44 monoclonal antibody. J. Neurosurg. (2000) 92(1):140-149.
108. COPE DA, DEWHIRST MW, FRIEDMAN HS, BIGNER DD, ZALUTSKY MR: Enhanced delivery of a monoclonal antibody F(ab′)2 fragment to subcutaneous human glioma xenografts using local hyperthermia. Cancer Res. (1990) 50(6):1803-1809.
109. 125I-labeled monoclonal antibody 425 to epidermal growth factor receptor. Cancer Res. (1992) 52(1):121-126.
110. LAMSZUS K, BROCKMANN MA, ECKERICH C et al.: Inhibition of glioblastoma angiogenesis and invasion by combined treatments directed against vascular endothelial growth factor receptor-2, epidermal growth factor receptor, and vascular endothelial-cadherin. Clin. Cancer Res. (2005) 11(13):4934-4940.
111. ZALUTSKY MR: Targeted radiotherapy of brain tumours. Br. J. Cancer (2004) 90(8):1469-1473.
112. RUBENSTEIN JL, KIM J, OZAWA T et al.: Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia (2000) 2(4):306-314.
113. KIM KJ, WANG L, SU Y et al.: Systemic anti-HGF monoclonal antibody therapy induces regression of intracranial glioma xenograft. Proc. Am. Assoc. Cancer Res. (2006) 47:267.
114. CROMBET T, TORRES O, RODRIGUEZ V et al.: Phase I clinical evaluation of a neutralizing monoclonal antibody against epidermal growth factor receptor in advanced brain tumor patients: preliminary study. Hybridoma (2001) 20(2):131-136.
115. LASKE DW, MURASZKO KM, OLDFIELD EH et al.: Intraventricular immunotoxin therapy for leptomeningeal neoplasia. Neurosurgery (1997) 41(5):1039-1049 (Discussion 1049-1051).
116. 90Y: a Phase I study. Clin. Cancer Res. (1999) 5(Suppl. 10):3275s-3280s.